Recently a number of randomized trials have shown that treatment of patients with advanced colorectal cancer (CRC) do not benefit from therapies targeting the epidermal growth factor receptor (EGFR) when their tumors harbor mutations in the KRAS, BRAF and PIK3CA genes [1], [2], [3]. This evidence concerns the gene KRAS and colorectal cancer.